242 related articles for article (PubMed ID: 21712452)
1. Treatment-induced oxidative stress and cellular antioxidant capacity determine response to bortezomib in mantle cell lymphoma.
Weniger MA; Rizzatti EG; Pérez-Galán P; Liu D; Wang Q; Munson PJ; Raghavachari N; White T; Tweito MM; Dunleavy K; Ye Y; Wilson WH; Wiestner A
Clin Cancer Res; 2011 Aug; 17(15):5101-12. PubMed ID: 21712452
[TBL] [Abstract][Full Text] [Related]
2. Role of CAAT/enhancer binding protein homologous protein in panobinostat-mediated potentiation of bortezomib-induced lethal endoplasmic reticulum stress in mantle cell lymphoma cells.
Rao R; Nalluri S; Fiskus W; Savoie A; Buckley KM; Ha K; Balusu R; Joshi A; Coothankandaswamy V; Tao J; Sotomayor E; Atadja P; Bhalla KN
Clin Cancer Res; 2010 Oct; 16(19):4742-54. PubMed ID: 20647473
[TBL] [Abstract][Full Text] [Related]
3. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation.
Pérez-Galán P; Mora-Jensen H; Weniger MA; Shaffer AL; Rizzatti EG; Chapman CM; Mo CC; Stennett LS; Rader C; Liu P; Raghavachari N; Stetler-Stevenson M; Yuan C; Pittaluga S; Maric I; Dunleavy KM; Wilson WH; Staudt LM; Wiestner A
Blood; 2011 Jan; 117(2):542-52. PubMed ID: 20956803
[TBL] [Abstract][Full Text] [Related]
4. Combination bortezomib and rituximab treatment affects multiple survival and death pathways to promote apoptosis in mantle cell lymphoma.
Alinari L; White VL; Earl CT; Ryan TP; Johnston JS; Dalton JT; Ferketich AK; Lai R; Lucas DM; Porcu P; Blum KA; Byrd JC; Baiocchi RA
MAbs; 2009; 1(1):31-40. PubMed ID: 20046572
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma.
Yang DT; Young KH; Kahl BS; Markovina S; Miyamoto S
Mol Cancer; 2008 May; 7():40. PubMed ID: 18489772
[TBL] [Abstract][Full Text] [Related]
6. Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma.
Moros A; Rodríguez V; Saborit-Villarroya I; Montraveta A; Balsas P; Sandy P; Martínez A; Wiestner A; Normant E; Campo E; Pérez-Galán P; Colomer D; Roué G
Leukemia; 2014 Oct; 28(10):2049-59. PubMed ID: 24721791
[TBL] [Abstract][Full Text] [Related]
7. The proteasome inhibitor bortezomib induces apoptosis in mantle-cell lymphoma through generation of ROS and Noxa activation independent of p53 status.
Pérez-Galán P; Roué G; Villamor N; Montserrat E; Campo E; Colomer D
Blood; 2006 Jan; 107(1):257-64. PubMed ID: 16166592
[TBL] [Abstract][Full Text] [Related]
8. The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib.
Dasmahapatra G; Patel H; Dent P; Fisher RI; Friedberg J; Grant S
Br J Haematol; 2013 Apr; 161(1):43-56. PubMed ID: 23360303
[TBL] [Abstract][Full Text] [Related]
9. PRDM1 is required for mantle cell lymphoma response to bortezomib.
Desai S; Maurin M; Smith MA; Bolick SC; Dessureault S; Tao J; Sotomayor E; Wright KL
Mol Cancer Res; 2010 Jun; 8(6):907-18. PubMed ID: 20530581
[TBL] [Abstract][Full Text] [Related]
10. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma in vitro and in vivo by down-regulation of the prosurvival ER chaperone BiP/Grp78.
Roué G; Pérez-Galán P; Mozos A; López-Guerra M; Xargay-Torrent S; Rosich L; Saborit-Villarroya I; Normant E; Campo E; Colomer D
Blood; 2011 Jan; 117(4):1270-9. PubMed ID: 21106982
[TBL] [Abstract][Full Text] [Related]
11. Noxa mediates bortezomib induced apoptosis in both sensitive and intrinsically resistant mantle cell lymphoma cells and this effect is independent of constitutive activity of the AKT and NF-kappaB pathways.
Rizzatti EG; Mora-Jensen H; Weniger MA; Gibellini F; Lee E; Daibata M; Lai R; Wiestner A
Leuk Lymphoma; 2008 Apr; 49(4):798-808. PubMed ID: 18398749
[TBL] [Abstract][Full Text] [Related]
12. Nuclear translocation of B-cell-specific transcription factor, BACH2, modulates ROS mediated cytotoxic responses in mantle cell lymphoma.
Chen Z; Pittman EF; Romaguera J; Fayad L; Wang M; Neelapu SS; McLaughlin P; Kwak L; McCarty N
PLoS One; 2013; 8(8):e69126. PubMed ID: 23936317
[TBL] [Abstract][Full Text] [Related]
13. Dissecting bortezomib: development, application, adverse effects and future direction.
Cao B; Li J; Mao X
Curr Pharm Des; 2013; 19(18):3190-200. PubMed ID: 23151134
[TBL] [Abstract][Full Text] [Related]
14. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
[TBL] [Abstract][Full Text] [Related]
15. Targeting the proteasome in mantle cell lymphoma: a promising therapeutic approach.
Bogner C; Peschel C; Decker T
Leuk Lymphoma; 2006 Feb; 47(2):195-205. PubMed ID: 16321849
[TBL] [Abstract][Full Text] [Related]
16. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
Leonard JP; Furman RR; Coleman M
Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
[TBL] [Abstract][Full Text] [Related]
17. The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.
Pérez-Galán P; Roué G; Villamor N; Campo E; Colomer D
Blood; 2007 May; 109(10):4441-9. PubMed ID: 17227835
[TBL] [Abstract][Full Text] [Related]
18. Proteasome inhibition in the treatment of cancer.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Cell Cycle; 2005 Feb; 4(2):290-6. PubMed ID: 15655370
[TBL] [Abstract][Full Text] [Related]
19. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
[TBL] [Abstract][Full Text] [Related]
20. Degrasyn potentiates the antitumor effects of bortezomib in mantle cell lymphoma cells in vitro and in vivo: therapeutic implications.
Pham LV; Tamayo AT; Li C; Bornmann W; Priebe W; Ford RJ
Mol Cancer Ther; 2010 Jul; 9(7):2026-36. PubMed ID: 20606045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]